Briana Contreras

Reading C-peptide alongside glucose could better predict which autoantibody-positive people will develop type 1 diabetes and detect treatment effects sooner.

Topical steroids remain first-line for chronic hand eczema, but long-term use can thin the skin and leave patients with poorly controlled disease.

Laura Ferris urges risk-based melanoma screening and highlights earlier immunotherapy, selective imaging, vaccine limits and new post–PD-1 options.

Patients with HS should get three to four months on a biologic before a switch, says a dermatologist who sees promise in oral JAK inhibitors.

With three FDA-approved biologics for hidradenitis suppurativa, Jennifer Hsiao, M.D., said patient preference and access often decide which comes first.

Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.

Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.

How LLM decision support reshapes dermatology care, helping non-specialists diagnose while navigating trust gaps, ambiguity, and hallucination risks at Fall Clinical Derm.

Real-world data at the 2026 Fall Clinical Dermatology Conference show dupilumab in children with atopic dermatitis cuts new allergies and asthma risk versus steroids.

Sagimet CEO David Happel shares insights on denifanstat, highlighting strong acne response, tolerability and optimism for a denifanstat U.S. trial.

Sagimet CEO David Happel says oral denifanstat could sharply cut antibiotic use in acne and be used before patients ever need isotretinoin.

Sagimet Biosciences’ denifanstat oral acne pill shows rapid, sustained lesion cuts and higher clear-skin rates in phase 3, offering an antibiotic-sparing option.

Breakthroughs in 2026 dermatology spotlight oral psoriasis drugs nearing biologics, weight-loss combos for PsA, personalized mRNA melanoma vaccines and expanding OTC acne options.

Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.

Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.

Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.

CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.

State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.

Tariffs on patented drugs broaden beyond Big Pharma, and exemptions, MFN deals and origin caps determine rates and potential price pressure.

Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.

Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.

8-year data show adjuvant Tagrisso boosts survival after surgery for EGFR-mutated NSCLC, reshaping early Lung Cancer care and adherence.

Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.

Only 19% use AI predictive models in cancer care despite strong belief in impact; 2026 Oncology Care Index highlights reimbursement, training, funding barriers.

AI pathology tool measures lung cancer treatment response after neoadjuvant chemoimmunotherapy with 91% accuracy, speeding NSCLC care while needing review for complete response.

AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.

Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.

Rybrevant (amivantamab) plus chemotherapy reached a 34.3-month median survival in EGFR exon 20 insertion-positive lung cancer, Johnson & Johnson said.

Northwell Health reports rising 9/11-linked cancer rates tied to Ground Zero debris, as oncology teams expand screening and treatment for survivors and responders.

Prime Therapeutics taps Manmohan Mahajan as CFO, aiming to curb rising drug costs and expand affordability programs for health plans.